We look forward to welcoming you to the 18th Plenary Meeting of the Czech Lymphoma Study Group, held on March 18–19, 2026, at the Don Giovanni Hotel in Prague. The program is available in the attachment below. Please note that elections to the CLSG Executive Board will take place during this plenary meeting via in-person voting.

Other Upcoming Hematology Conferences in 2026:

• Olomouc Hematology Days 2026 | May 20–22, 2026 (NH Collection Congress, Olomouc)
• EHA 2026 (European Hematology Association) | June 11–14, 2026 (Stockholm, Sweden)
• ASH 2026 (American Society of Hematology) | December 12–15, 2026 (New Orleans, USA)

Upcoming CLSG Plenary Meetings in 2027 and 2028:

• March 17–18, 2027
• March 22–23, 2028

Upcoming HEMATOLOGY Conferences in Prague in 2027 and 2028:

• January 27–29, 2027
• January 26–28, 2028

The medicinal product Polivy, in combination with bendamustine and rituximab (Polivy + BR), was previously granted temporary reimbursement as a Highly Innovative Medicinal Product ("VILP") under administrative proceedings (Ref. Nos. SUKLS180061/2020 and SUKLS118045/2021). Please be advised that this public health insurance coverage expired on August 31, 2025, and is no longer in effect as of September 1, 2025.

We invite you to explore a comprehensive review of the highlights from the XXXVII Olomouc Hematology Days. Access the expert recap, including key takeaways and session summaries, via this link.

This year’s Prague "Hematology 2026" brought together a diverse range of experts, including clinicians, researchers, and healthcare professionals from both the Czech Republic and abroad. Follow this link to explore the insights, observations, and key takeaways shared by our attendees.

The 17th CLSG Plenary Meeting featured a diverse range of expert contributions from both Czech and international speakers. Key highlights included the latest advances in mantle cell lymphoma (MCL) and marginal zone lymphomas. The program also presented complex case reports highlighting diagnostic challenges, the importance of multidisciplinary collaboration, and new real-world evidence. Beyond therapeutic innovations, the conference focused on optimizing care pathways across hematology departments to ensure high-quality, standardized treatment. Listen to details.